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Abstract
The MUC1 protein is aberrantly expressed on an estimated 75% of all human solid tumor cancers. We recently reported that
a transmembrane cleavage product, MUC1*, is the predominant form of the protein on cancer cells [1]. Further, our
evidence indicated that MUC1* functions as a growth factor receptor on tumor cells, while the full-length protein appeared
to have no growth promoting activity. Here, we report that MUC1* acts as a growth factor receptor on undifferentiated
human embryonic stem cells (hESCs). Cleavage of the full-length ectodomain to form MUC1*, a membrane receptor,
appears to make binding to its ligand, NM23, possible. Unexpectedly, we found that newly differentiated cells no longer
express the cleaved form, MUC1*, or its ligand, NM23. Newly differentiated stem cells exclusively present full-length MUC1.
Antibody-induced dimerization of the MUC1* receptor on hESCs stimulated cell growth to a far greater degree than
currently used methods that require the addition of exogenous basic fibroblast growth factor (bFGF) as well as factors
secreted by fibroblast ‘‘feeder cells’’. Further, MUC1* mediated growth was shown to be independent of growth stimulated
by bFGF or the milieu of factors secreted by feeder cells. Stimulating the MUC1* receptor with either the cognate antibody
or its ligand NM23 enabled hESC growth in a feeder cell-free system and produced pluripotent colonies that resisted
spontaneous differentiation. These findings suggest that this primal growth mechanism could be utilized to propagate large
numbers of pluripotent stem cells for therapeutic interventions.
Citation: Hikita ST, Kosik KS, Clegg DO, Bamdad C (2008) MUC1* Mediates the Growth of Human Pluripotent Stem Cells. PLoS ONE 3(10): e3312. doi:10.1371/
journal.pone.0003312
Editor: Nils Cordes, Dresden University of Technology, Germany
Received May 19, 2008; Accepted September 6, 2008; Published October 3, 2008
Copyright:  2008 Hikita et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Dr. Ken Kosik is supported in part by the W.M. Keck Foundation. The Center for Stem Cell Biology and Engineering was supported by grants from the
California Institute for Regenerative Medicine, Advanced Cell Technology, Inc., Chemicon / Millipore Corp., the TriCounties Blood Bank, Santa Barbara Cottage
Hospital, and private individuals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Drs. Kosik and Bamdad are shareholders in Minerva Biotechnologies.
* E-mail: cbamdad@minervabio.com
Introduction
Stem cells are classified as totipotent, pluripotent or multipotent.
A totipotent stem cell, such as a fertilized egg, is capable of
developing into a complete organism. Pluripotent stem cells,
exemplified by undifferentiated embryonic cells, are able to
develop into any cell or tissue type. Multipotent stem cells, found
for example in bone marrow, are able to develop into a limited
subset of cell types. Pluripotent stem cells hold the greatest promise
for therapeutic use because they possess the ability to become
virtually any cell type in the human body. In principal, pluripotent
stem cells could be used to replace damaged tissues in organs that
have traditionally been thought not to have a significant potential
for functional self-repair such as heart muscle, spinal cord, brain
tissue and kidney [2–6]. However, to implement these therapies,
one must have the ability to produce a replenishable supply of
pluripotent stem cells, on a large scale, that can then be induced to
differentiate into the desired cell types. Certain technical hurdles
must be overcome before clinical therapies using pluripotent stem
cells can become a reality.
First, improved methods for propagating pluripotent stem cells
and ensuring their pluripotency must be developed. Currently, it is
not possible to culture embryonic stem cells (ESCs) without
initiating some degree of spontaneous differentiation. Growing
ESCs under optimized conditions yields only about 65–75%
undifferentiated, pluripotent stem cells. The remainder spontane-
ously differentiate. This is a problem because the cells that have
initiated differentiation appear to secrete factors that encourage
neighboring cells to also differentiate. To maintain a useful supply
of pluripotent stem cells, the undifferentiated colonies, or portions
of those colonies, must be manually dissected away from those that
have begun to differentiate, then re-plated for further growth. This
process is labor intensive and inaccurate because it depends upon
the technician’s visual assessment of cell and colony morphology in
the determination of which colonies remain undifferentiated. An
additional problem is that there is an upper limit of about 100
generations that embryonic stem cells can be passaged before they
lose pluripotency. Higher passage numbers often correlate with
increased risk of abnormal karyotypes or genetic drift, wherein
abnormal cells with a selective growth advantage overtake and
suppress the pluripotent population [7].
The state of the art for culturing hESCs requires the addition of
a milieu of poorly understood factors from fibroblast ‘‘feeder
cells’’. Some of these factors appear to be necessary to maintain
the undifferentiated state, while others likely trigger differentiation.
Factors secreted from fibroblasts are supplied either by growing
the hESCs over a layer of fibroblast feeder cells [8] or by growing
the stem cells over matrigel-coated surfaces and feeding with
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from fibroblasts [9]. Basic fibroblast growth factor (bFGF) has
been identified as a mitogenic factor that helps maintain cultures
in the undifferentiated state and is added to stem cell growth
media for optimal yield of undifferentiated stem cells [10].
There is also the need for improved methods for identifying and
isolating pluripotent stem cells from a mixed pool of undifferen-
tiated and differentiated cells. It is evident that local environment
plays a critical role in the process of stem cell differentiation.
Pluripotent stem cells can be influenced to differentiate into
particular cell types when grown over more mature cells [11]. It
may be that transplanted pluripotent stem cells differentiate into
the cell type of the local environment in response to factors
secreted by those cells/tissues. One can imagine that the
contamination of pluripotent stem cells with even a small number
of cells that have already committed to a particular differentiation
pathway would be sufficient to confound the ordered differenti-
ation process in a way that could have disastrous outcomes.
Whether stem cells are transplanted as pluripotent or at an
intermediate stage of tissue type differentiation, successful stem cell
treatments may benefit from pure populations of stem cells and a
detailed understanding of the molecular triggers that initiate the
various steps along the path from undifferentiated to mature cell.
Reliable, high throughput methods for rapidly identifying and
isolating pluripotent stem cells, in a manner that preserves cell
viability, have not yet been developed.
Therefore, what are needed are methods to identify and isolate
pluripotent stem cells, to propagate pure populations in the
undifferentiated state and to understand the molecular mecha-
nisms that maintain pluripotency as well as those that trigger
differentiation. To that end, we focused upon mechanisms that
drive malignant growth related to so-called tumor stem cells. We
focused on a cell surface protein that appears to mediate the
growth of a large class of cancer cells and asked if it also mediates
the growth of stem cells. This protein, MUC1, is a transmembrane
protein that is expressed on normal epithelia that line the
respiratory, reproductive and gastrointestinal tracts. On healthy
tissue, MUC1 is clustered at the apical border. But, on cancerous
tissues MUC1 is over-expressed and uniformly distributed over the
entire cell surface [12,13]. An estimated 75% of all human solid
tumor cancers aberrantly express the MUC1 protein [14]. The
role of MUC1 in the healthy state has not been studied as
extensively as its role in cancer, where there is significant evidence
that it promotes tumor cell growth and survival [15–18].
In a recent article, we showed that a membrane-anchored
MUC1 cleavage product, MUC1*, that retains only 45 amino
acids of the original extracellular domain, is the predominant form
of the protein on human cancerous tissues; the bulk of the
extracellular domain is cleaved and shed from the tissue surface
[1]. We further demonstrated that MUC1* has growth factor
receptor-like activity wherein ligand-induced dimerization of the
short extracellular domain activates the MAP kinase signaling
pathway and stimulates cell growth. Blocking the ligand binding
site of the extracellular domain inhibited cell growth in a dose-
dependent manner. The purpose of the present studies was to
investigate the possible roles of the two forms of the MUC1
protein, MUC1* and full-length MUC1, in the growth and
differentiation of human embryonic stem cells.
Results
We used three antibodies to probe the expression of MUC1 on
hESCs: two that recognize the full-length protein (MUC1-FL) and
one that recognizes the cleavage product, MUC1*. Both VU4H5
and HMPV are commercially available antibodies that bind to
epitopes in the tandem repeats of the full-length protein (Fig. 1A).
VU4H5 preferentially binds to underglycosylated MUC1, while
HMPV recognizes full-length MUC1 in a glycosylation-indepen-
dent manner and can bind to the fully glycosylated protein. Anti-
MUC1* is a rabbit polyclonal antibody that was raised against a
synthetic peptide that corresponds to the first forty-five (45)
membrane-proximal amino acids of the extracellular domain,
which comprises most if not all of the extracellular domain of the
cleavage product, MUC1* (Fig. 1B). As we previously reported
[1], although the epitope for Anti-MUC1* is present in the full-
length protein, Anti-MUC1* does not bind to MUC1-FL when
analyzed by Western blot or immunocytochemistry. Immunopre-
cipitation experiments show that Anti-MUC1* reacts very weakly
with MUC1-FL. One possible explanation is that full-length
MUC1 contains a self-aggregation domain that likely contributes
to the protein’s characteristic clustering and could sterically hinder
the binding of ligands to the adjacent region which is the Anti-
MUC1* epitope. Cleavage of MUC1 on cancer cells releases the
bulk of the extracellular domain, including most if not all of the
self-aggregation domain. It is not known whether or not Anti-
Figure 1. Schematic and antibody recognition of full-length MUC1 versus the membrane-bound cleavage product MUC1*. A. Full-
length MUC1 protein (MUC1-FL) is comprised of a cytoplasmic tail (CT), a transmembrane domain (TM), a self-aggregation domain (SAD), and
hundreds of tandem repeats (TRs). B. Cleavage product, MUC1*, consists of the cytoplasmic tail, transmembrane domain, and at least 45 amino acids
of the extracellular domain (ECD). Although the exact site(s) of cleavage remain somewhat uncertain, to our knowledge, no cleavage sites have been
reported that leave less than a 45 amino acid ECD. Binding sites for antibodies VU4H5 and Anti-MUC1* are marked.
doi:10.1371/journal.pone.0003312.g001
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MUC1/Y or MUC1/Z [19,20], which, like MUC1*, contain the
Anti-MUC1* epitope and lack the tandem repeat region; one way
that they differ from MUC1* is that their extracellular domains
are more than one hundred (100) amino acids longer and contain
the self-aggregation domain. Although MUC1/Y is not cleaved, it
has been reported that MUC1/X/Z can be cleaved to yield a
membrane-attached fragment that is essentially indistinguishable
from the MUC1-FL cleavage product [21], and thus would likely
be recognized by Anti-MUC1*.
MUC1 Expression on Human Embryonic Stem Cells
Immunofluorescent cytochemistry experiments were performed
on H9 and H14 human embryonic stem cells (hESCs). The stem
cells were probed with Anti-MUC1*, VU4H5 and HMPV as well
as with antibodies against a panel of known markers of the
undifferentiated state [22,23]. Both undifferentiated and differen-
tiated hESCs were analyzed. Undifferentiated hESCs were
obtained by culturing them under conditions that have been
shown to support the undifferentiated state, followed by manual
dissection of colonies that morphologically appeared to be
undifferentiated, and plating onto chamber slides for further
growth and antibody staining. At this final stage, cells were
deemed to be undifferentiated if they stained positive for OCT4
[24]. hESCs were induced to differentiate by withholding
exogenous bFGF for 14 days or longer [25]. Differentiation was
confirmed, by visual inspection, testing negative for the presence of
OCT4, and testing positive for the presence of the three germline
markers: alpha fetoprotein for endoderm [26], smooth muscle
actin for mesoderm [27], and nestin for ectoderm [28]. Stem cells
used in these experiments were shown to be of normal karyotype
(Fig. S1).
Immunocytochemistry experiments showed that MUC1* is
highly expressed on undifferentiated hESCs; double staining
experiments with an antibody against OCT4 confirmed that the
cells that expressed MUC1* were in fact undifferentiated stem cells
(Fig. 2A). DAPI staining revealed that both MUC1* and OCT4
were expressed by essentially all the undifferentiated cells (data not
shown). Figure 2B shows that MUC1* expression also co-localized
with SSEA4, another marker for undifferentiated hESCs [29],
although expression between these two did not always precisely co-
localize. MUC1* co-localized to a similar extent on undifferen-
tiated hESCs with Tra 1–81 and Tra 1–60 [30] which are also
indicators of the undifferentiated state (Figs. 2 C,D). MUC1*
appears to be surface-expressed as evidenced by antibody staining
in the absence of added detergent (Figs. 2 B–D). Control
experiments for all immunocytochemistry imaging are shown in
Figure S6.
Unexpectedly, we found that although the cleaved form,
MUC1*, is highly expressed on undifferentiated hESCs, no full-
length MUC1 was detectable. Undifferentiated stem cells stained
positive for MUC1* and OCT4 but negative for full-length
MUC1 (Fig. 3A–C). In stark contrast, newly differentiated
embryonic stem cells exclusively expressed full-length MUC1 but
not the cleaved form, MUC1*. Differentiating stem cells tested
positive for full-length MUC1 and negative for both MUC1* and
OCT4 (Fig. 3D–F). No full-length MUC1 was detectable on
undifferentiated H9 or H14 hESCs, whether probed with the
VU4H5 antibody or HMPV; after differentiation, both cell lines
stained positive for MUC1-FL using either antibody (Fig. S2 A–H;
Fig. S3 A–F). Both cell lines stained positive for the presence of
MUC1* in the undifferentiated state, but not in the differentiated
state (data not shown). We cannot rule out the possibility that Anti-
MUC1* is also staining an alternative splice isoform such as
MUC1/X, MUC1/Y or MUC1/Z. However, Western blot
analysis of H9 hESCs revealed a 20 kD Anti-MUC1* reactive
species that co-migrated with the MUC1 cleavage product from
T47D breast cancer cells and with transfected MUC1*1110, that
contains only forty-five (45) amino acids of the extracellular
domain (Fig. S4). It follows that this low molecular weight species
is the cleavage product of full-length MUC1, since it runs with an
apparent molecular weight that is roughly half the apparent
molecular weight of MUC1/Y and MUC1/Y is not cleaved.
We further investigated the observed switch from MUC1* to
MUC1-FL as stem cells enter the differentiation process. Closer
inspection of many antibody-stained colonies revealed that there
were rare transition regions that simultaneously expressed OCT4,
the gold-standard marker for pluripotency, and full-length MUC1,
which appears to be a marker for differentiation. Figure 4A–C
shows that the edge of a colony that has begun to differentiate
simultaneously expressed OCT4 and MUC1-FL. Other transition
zones expressed MUC1-FL, MUC1* and OCT4 (Fig. 4D–I). It is
notable that within these mixed populations, MUC1* appeared to
faithfully co-localize with OCT4, while OCT4 sometimes co-
localized with MUC1-FL.
Expression of MUC1 Cleavage Enzymes on hESCs
MMP14 (MT1-MMP) and TACE (ADAM 17) have been
reported to be enzymes that cleave MUC1 on human uterine
epithelial cells [31,32]. If MMP-14 and TACE also cleave MUC1
on embryonic stem cells, then one might expect high expression
levels on undifferentiated cells, where MUC1 is cleaved, and lower
expression on differentiating cells where it is not. Immunofluores-
cent imaging revealed that both cleavage enzymes, MMP14 and
TACE, are robustly expressed on undifferentiated stem cells that
were completely devoid of full-length MUC1 (Fig. 5A–C).
However, on newly differentiated stem cells, where MUC1-FL
immunoreactivity was present, there was a marked decrease in
MMP14 and TACE expression (Fig. 5 D–F). The merged image of
a triple staining experiment, which also included DAPI staining,
shows that approximately 50% of the cells present stained positive
for the cleavage enzymes (Fig. 5F) compared to virtually 100% on
undifferentiated colonies (data not shown). These findings support
the idea that cleavage enzymes MMP14 and TACE cleave MUC1
on embryonic stem cells.
MUC1* Ligand Expression on hESCs
NM23 is normally a cytoplasmic protein but is often secreted by
tumor cells [33]. It can exist as a monomer, dimer, tetramer or
hexamer, depending upon concentration [34]. NM23 has recently
been identified as a ligand for MUC1* that stimulates the growth
of tumor cells by dimerizing two MUC1* receptors [1]. We,
therefore, looked for NM23 expression by hESCs. Figure 6 A–C
depicts a triple staining experiment in which a hESC colony was
stained with DAPI and antibodies against NM23 and MUC1*.
The merged image (Fig. 6C) shows that expression of MUC1* and
NM23 precisely co-localize, but are not expressed on newly
differentiating cells at the edge of the colony. Another colony that
had been stained with DAPI and antibodies against NM23 and
OCT4 confirms that NM23-positive cells were in fact undifferen-
tiated. Differentiated hESCs did not stain positive for the presence
of NM23 (Fig. 6 D–F). These results are consistent with the idea
that NM23 could also be a ligand of MUC1* on hESCs.
MUC1*-Mediated Stem Cell Growth
We previously reported that [1], bivalent Anti-MUC1*,
stimulated the growth of MUC1-positive tumor cells, whereas
the monovalent Fab fragment of that same antibody potently
Pluripotent Stem Cells
PLoS ONE | www.plosone.org 3 October 2008 | Volume 3 | Issue 10 | e3312inhibited growth. Experiments indicated that the bivalent antibody
dimerized the MUC1* receptor, which activated the MAP kinase
proliferation pathway, but the monovalent Fab blocked the
interaction between MUC1* and its native ligand NM23. We
were also able to demonstrate that NM23, and in particular the
mutant that preferentially forms dimers [35], like the bivalent
antibody, stimulated the growth of MUC1-positive tumor cells.
We performed similar experiments to determine whether
ligands of MUC1* could mediate the growth of pluripotent
hESCs. Undifferentiated stem cells were grown on matrigel-coated
wells and cultured according to current methods which included
feeding with minimal stem cell media that had been supplemented
with 30% conditioned media from Hs27 fibroblast feeder cells.
Cells were treated with bivalent Anti-MUC1* or the monovalent
Fab, in the presence or absence of exogenous bFGF. The addition
of Anti-MUC1* to undifferentiated hESCs had a dramatic,
stimulatory effect on cell growth. Treating hESCs with bivalent
Anti-MUC1* for forty-one (41) hours, in the presence or absence
of added bFGF, resulted in cells that were more viable and
abundant than control cells that were cultured according to
standard methods, which included adding bFGF. In stark contrast,
the addition of the monovalent Fab fragment of Anti-MUC1*
Figure 2. MUC1* co-localizes with OCT4 and other markers of pluripotency on undifferentiated human embryonic stem cells
(hESCs). Undifferentiated H9 hESCs were cultured according to standard methods on chamber slides then double stained with Anti-MUC1* and
antibodies that recognize known markers of pluripotency: A. MUC1* is co-expressed with OCT4 on undifferentiated hESCs. B. MUC1* and SSEA4 co-
localize to a great extent on undifferentiated hESC colonies. C. MUC1* and Tra 1–81 partially co-localize on undifferentiated hESC colonies. D. MUC1*
and Tra 1–60 are co-expressed on hESCs. Dotted lines indicate the border of the undifferentiated colony. Scale bars=100 mm.
doi:10.1371/journal.pone.0003312.g002
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protein (MUC1-FL) is expressed on differentiated stem cells. A–C. Undifferentiated H9 hESC colonies were triple stained with antibodies
against: A. MUC1*, B. OCT4, and C. MUC1-FL. The dotted line indicates the border of the undifferentiated colony. D–F. H9 hESC colonies were
induced to differentiate by withholding bFGF for 14 days. Visual inspection indicated that the colonies had differentiated. The hESC colonies were
triple stained with antibodies against: D. MUC1*, E. OCT4, and F. MUC1-FL. Scale bars=100 mm.
doi:10.1371/journal.pone.0003312.g003
Figure 4. Transition zones between undifferentiated and differentiated hESCs simultaneously express full-length MUC1 and OCT4.
hESCs grown without bFGF for 14 days appeared to be MUC1-FL positive and OCT4/MUC1* negative. However, rare transition regions were found
that expressed all three proteins. A–C. The leading edge of an undifferentiated stem cell colony that has begun to differentiate stains positive for: A.
MUC1-FL. B. OCT4. C. The merged image shows that MUC1-FL and OCT4 are expressed by the same cells. The border between undifferentiated and
differentiated portions of the colony is marked by the dotted line. D–F. Another transition region simultaneously expressed: D. MUC1-FL. E. MUC1*.
F. OCT4. However, tracking of individual cells indicates that MUC1* appears to faithfully co-localized with OCT4. Scale bars=100 mm.
doi:10.1371/journal.pone.0003312.g004
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(Fig. 7A–F). Presumably the monovalent Fab competed with
MUC1*’s native ligand, NM23, for binding and blocked receptor
dimerization. The growth effects of the MUC1*-targeting
antibodies were quantified by measuring the fluorescence at
530 nm for live cells grown under each test condition. In the
absence of added exogenous bFGF, the addition of bivalent Anti-
MUC1* resulted in a greater than 2-fold enhancement of cell
growth compared to the control (Fig. 7G). A plot of normalized
cell growth with added bFGF defined as 100%, is shown in
Figure 7H. Bivalent Anti-MUC1* greatly enhances the growth of
undifferentiated stem cells and does not require the addition of
exogenous bFGF. Notably, the addition of bFGF cannot rescue
stem cells when treated with monovalent Anti-MUC1*. A similar
experiment was performed in which the effects of bivalent Anti-
MUC1*, its monovalent Fab, and a control Fab, on H9 and on
H14 hESCs were measured (Fig. S5 A,B). The results were
essentially the same as those depicted in Figure 7.
Since it appeared that MUC1*-mediated growth of hESCs was
independent of the addition of basic fibroblast growth factor
(bFGF), we investigated whether or not MUC1*-mediated growth
required any fibroblast-derived factors. Specifically, we tested
whether or not the addition of the MUC1* dimerizing antibody
was sufficient to support the long-term growth of pluripotent
hESCs in minimal media and in the absence of fibroblast feeder
cells, their extracts, or purified bFGF. Undifferentiated H9 hESCs
were plated at very low density onto matrigel and cultured for five
weeks in either minimal stem cell media or minimal media
supplemented with 30% conditioned media from Hs27 fibroblast
feeder cells. The stem cells were treated every 48 hours with
either: a) nothing; b) bFGF; c) bivalent Anti-MUC1*; or d) bFGF
and bivalent Anti-MUC1*. Throughout the course of treatment,
the plates were inspected for the appearance of new colonies.
Their numbers and morphology were recorded and tabulated in
Table 1.
In the absence of conditioned media from fibroblast feeder cells,
the only condition that supported the growth of pluripotent stem
cells was the addition of Anti-MUC1*, alone (Table 1). The
condition that included Anti-MUC1* and bFGF did not produce
any pluripotent cells, nor did the addition of bFGF alone. The
addition of Anti-MUC1* produced the first colony, the largest
colony (completely covered the well) and after five weeks of
stimulation with Anti-MUC1* itremained 100%positiveforOCT4
(Fig. 8A,B). Stem cells grown under these conditions did not
spontaneously differentiate. However, the withdrawal of the Anti-
MUC1* antibody, after five weeks, did induce the onset of
differentiation. None of the other conditions tested produced any
OCT4-positive cells when grown in the absence of conditioned
media from fibroblasts. Stem cells grown in minimal media that had
been supplemented with conditioned media from fibroblast feeder
cells produced a mixture of undifferentiated and differentiated
colonies in response to treatment with Anti-MUC1* (Fig. 8C,D) or
bFGF (Fig. 8E,F). However, treatment with Anti-MUC1* produced
colonies sooner and produced more undifferentiated cells than
Figure 5. The expression of MUC1 cleavage enzymes, MMP14 and TACE, is high on undifferentiated hESCs but significantly lower
on differentiated cells. A–C. Stem cells colonies that were deemed to be undifferentiated by visual inspection and by staining positive for the
presence of OCT4 were stained with antibodies against MUC1-FL and the cleavage enzymes. A. Undifferentiated hESC colonies were stained with an
antibody that recognizes MMP14. VU4H5, which recognizes MUC1-FL, did not stain this colony (data not shown). B. Undifferentiated hESC colonies
were stained with an antibody that recognizes TACE. C. The same undifferentiated colony was also treated with VU4H5 (binds to MUC1-FL) but no
immuno-reactivity was detected. D–F. Stem cells that were induced to differentiate by withholding bFGF for 14 days were stained with the same
antibodies as in A–C. D. Newly differentiating stem cell colonies co-express MMP14 (red) and MUC-FL (green). E. Similarly, newly differentiating stem
cell colonies co-express MUC1 cleavage enzyme TACE (red) and MUC1-FL (green). F. Triple staining of colonies with anti-TACE (red), VU4H5 (green)
and DAPI (blue) showed that roughly 50% of the differentiating cells expressed the cleavage enzyme. An experiment using an antibody against
MMP14 gave essentially the same result. Scale bars=100 mm.
doi:10.1371/journal.pone.0003312.g005
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and Anti-MUC1, together, did not support the growth of
undifferentiated colonies in either media (Fig. 8E,F).
To verify that the stimulation of stem cell growth that we
observed was in fact due to the activation of the MUC1* receptor,
we measured the stimulatory effect of Anti-MUC1* as a function
of antibody concentration. H9 hESCs were plated at
1.9610
4 cells/well (in triplicate) on matrigel-coated 96-well plates.
Cells were cultured in minimal media without any added fibroblast
extracts or growth factors. Anti-MUC1* was added at concentra-
tions that ranged from 0 to 2 ug/ml. Media plus antibody was
changed every other day. After ten (10) days most wells had
reached 75% confluency. Cell numbers were measured by staining
with Amido Black and measuring absorbance at 570 nm. A plot of
cell growth as a function of antibody concentration indicates that
the bivalent antibody stimulates stem cell growth in a dose-
dependent manner (Fig. 9). A control experiment performed in
parallel, wherein stem cells were plated at the same density but
grown according to standard protocol which included the addition
of 30% conditioned media from fibroblast feeder cells and
exogenous bFGF. The degree of cell growth that was achieved
using the state of the art conditions is denoted on the graph.
Our studies next focused on whether the MUC1* ligand,
NM23, could also stimulate embryonic stem cell growth and/or
support the growth of pluripotent stem cells in a feeder-free
system. H9 hESCs were seeded at 1.2610
5 cells/well in 24-well
plates and cultured for eight (8) days, supplemented with either
nothing, bFGF, Anti-MUC1*, recombinant NM23 or NM23-
S120G, which is a mutant that preferentially forms dimers. The
results are shown in Table 2. The ligand of MUC1*, NM23, also
stimulated and supported embryonic stem cell growth in minimal
media devoid of bFGF or feeder-cell extracts. NM23, NM23-
S120G and Anti-MUC1* all produced undifferentiated stem cell
colonies. Neither the addition of bFGF nor the null control
produced any stem cell colonies. As a control, an aliquot of the
cells was plated at the same density and grown in 50% conditioned
media from Hs27 fibroblasts and bFGF. During the eight-day
growth period, this condition generated single undifferentiated
cells, but no colonies.
Another long-term growth experiment was performed to assess
the effects of Anti-MUC1*, NM23wt and NM23-S120G on the
rate of stem cell growth and their differentiation state. Results are
summarized in Table 3. After four (4) weeks of culturing H14
embryonic stem cells in minimal stem cell media, and in the
absence of conditioned media from fibroblast feeder-cells or
bFGF, cells treated with either Anti-MUC1* or NM23 grew faster,
formed colonies sooner and resisted the onset of differentiation to a
far greater degree than state of the art methods.
Discussion
We have shown that undifferentiated embryonic stem cells do
not express full-length MUC1. Rather, they express a low
molecular weight cleavage product, MUC1*, which we previously
demonstrated has growth factor receptor-like activity on tumor
cells. NM23, which was shown to be an activating ligand of
MUC1* on cancer cells, co-localizes with MUC1* on pluripotent
cells. Unexpectedly, we found that newly differentiated cells no
longer express cleaved MUC1* or its ligand, NM23. Newly
differentiated stem cells present full-length MUC1. Transition
zones between undifferentiated and differentiating cultured stem
cells can be found that continue to express OCT4, while also
expressing uncleaved, full-length MUC1, which appears to be a
marker for the onset of differentiation. Thus, the switch from
Figure 6. The MUC1* ligand, NM23, co-localizes with MUC1* and OCT4 on undifferentiated hESCs but immuno-reactivity of all
three proteins is lost in the portion of the colony that has begun to differentiate. Undifferentiated H9 hESC colonies stained positive for
NM23, MUC1* and OCT4. Newly differentiating colonies did not react with antibodies against any of the three proteins. Co-expression of NM23 with
OCT4 and MUC1* is best seen in colonies that have begun to differentiate. The dotted line marks the border between undifferentiated and
differentiated portions of the colonies. Triple staining experiments were performed using: A. anti-NM23 (green). B. Anti-MUC1* (red). C. anti-NM23
(green), anti-MUC1* (red) and DAPI (blue). A similar colony was stained with: D. anti-NM23 (green). E. anti-OCT4 (red). F. anti-NM23 (green), anti-
OCT4 (red) and DAPI (blue). Scale bar=100 mm.
doi:10.1371/journal.pone.0003312.g006
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detectable signals of the onset of differentiation. These results
imply that MUC1* may be a more accurate marker of
pluripotency than OCT4 and thus antibodies that recognize
MUC1* could be used to search for, identify and isolate pure
populations of pluripotent stem cells. Anti-MUC1* has been used
extensively in our labs to effectively identify and sort both live and
fixed MUC1*-positive cancer cells using FACS. These methods
can be readily extended to identifying and sorting live embryonic
stem cells, which could automate and improve the procedure for
separating out stem cells that remain pluripotent from those that
have begun to differentiate. At present this is an imprecise and
labor-intensive process that depends on the technician’s ability to
visually discriminate between cell types then manually dissect
pluripotent cells without contaminating the pool with cells that
have already entered the differentiation process.
Figure 7. MUC1* mediates growth of pluripotent human embryonic stem cells. Undifferentiated H9 hESCs were grown for 41 hours in the
presence of bivalent Anti-MUC1* (Bivalent Ab), which can dimerize the receptor, the monovalent Fab of Anti-MUC1* (Monovalent Ab), that blocks
receptor dimerization, and/or basic fibroblast growth factor (bFGF). The results were quantified as follows. A–F. A live/dead (green/red) calcein assay
was performed 41 hours post treatment. Photos record the results. A. Treatment with bivalent Anti-MUC1* (Bivalent Ab) and bFGF produced mostly
viable cells (green) and very few dead cells (red). B. Treatment with the monovalent Fab of Anti-MUC1* (Monovalent Ab) and bFGF resulted in
essentially total cell death within 12 hours. C. Treatment with bFGF alone produced mostly viable cells. D. Treatment with bivalent Anti-MUC1* alone
produced more viable cells than with the addition of bFGF. E. Treatment with monovalent Anti-MUC1* killed essentially all cells. F. Treatment
without antibodies or bFGF resulted in more dead cells and less viable cells. G. A bar graph shows that after 41 hours of treatment with Anti-MUC1*
(Bivalent Antibody) there were more than 2-times the number of live cells than without the antibody (No Ab). Treatment with the monovalent Fab
(Monovalent Ab) killed all the cells. Fluorescence of live cells in a calcein assay is plotted. Data are represented as mean fluorescence units6SEM. H.
The percentage hESC growth is plotted for undifferentiated cells grown in the presence or absence of bFGF and with bivalent or monovalent Anti-
MUC1* (Bivalent Ab, Monovalent Ab). Student’s two-tailed test was used for statistical analysis. The graph shows that Anti-MUC1* with or without
bFGF stimulated growth roughly twice as well as with bFGF.
doi:10.1371/journal.pone.0003312.g007
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receptor on pluripotent embryonic stem cells. Under conditions
that included adding conditioned media from fibroblast feeder
cells, antibody-induced dimerization of the extracellular domain of
MUC1* stimulated the growth of hESCs more than two-fold
better than current methods and importantly without requiring the
addition of exogenous bFGF. Further, the addition of MUC1*
dimerizing ligands, Anti-MUC1* or NM23, enabled the growth of
pluripotent stem cells in feeder-cell-free and bFGF-free minimal
growth media. In fact, stem cell growth supported by the addition
of MUC1* ligands to minimal media resisted spontaneous
differentiation and produced more pluripotent cells than any
other growth condition that we tested. In contrast, neither minimal
stem cell growth media nor media plus bFGF produced any
undifferentiated stem cells. Stem cells that were cultured in
conditioned media from fibroblasts plus bFGF generated a
mixture of undifferentiated and differentiated colonies and the
colonies were smaller than those produced by MUC1* stimulation.
Thus, in addition to mediating the growth of embryonic stem cells,
MUC1* may be a modulator of differentiation. The data
presented strongly suggest that MUC1* is a critical marker for
the identification and isolation of pluripotent embryonic stem cells
as well as a key mediator of the growth and differentiation of
pluripotent stem cells.
Methods
Anti-MUC1* Antibodies
Polyclonal: Rabbits were immunized with a synthetic peptide
corresponding to the first forty-five (45) amino acids of the
extracellular domain, GTINVHDVETQFNQYKTEAASPYNL-
TISDVSVSDVPFPFSAQSGA, conjugated at the C-terminus
with KLH and affinity purified by column chromatography.
Papain digestion, then purification over a protein A column
produced monovalent Anti-MUC1*, collected from the flow-
through (QCB). The specificity of Anti-MUC1* was extensively
characterized by Western, FACS, immunocytochemistry, co-
immunoprecipitation, and nanoparticle experimentation [1].
ES Cells and Culture
H9 or H14 hESCs (WiCell) were cultured at 37uC and 5% CO2
on either mitomycin-C inactivated Hs27 human foreskin fibro-
blasts (ATCC) in 6 well plates (BD Falcon). hESC culture media
consisted of DMEM/F12/GlutaMAX I with 20% Knockout
Serum Replacement, 1% non-essential amino acids stock, 0.1 mM
b-mercaptoethanol (all from Invitrogen) and 4 ng/ml human basic
fibroblastic growth factor (bFGF, Peprotech). Cells were passaged
by manual dissection every 5–7 days at a ratio of 1:3 and medium
was changed every 48 hours. In some experiments, hESCs were
grown on matrigel (BD Biosciences) with hESC culture media
supplemented with 30% Hs27-conditioned medium and 4 ng/ml
bFGF. In other experiments in which Anti-MUC1* was added,
conditioned media and bFGF were omitted.
Immunofluorescence of ES Cells
Manually dissected H9 or H14 cells were plated in 8-well
chamber slides (Nunc) either pre-seeded with mitomycin-C
inactivated Hs27 human foreskin fibroblasts or pre-coated with
matrigel. For undifferentiated cells, cells were fixed 5–7 days after
plating. For differentiated cells, bFGF was removed from the
Table 1. H9 hESCs cultured in minimal media for five weeks.
Growth Conditions Time to First Visible Undifferentiated Colony Morphology
Week 1 Week 2 Week 3 Week 4
30% Conditioned Media from Hs27 Fibroblast Feeder Cells
nothing - - - - 3/4 wells fibroblast-like cells; 1/4
wells also had 1 small OCT4
2
colony
bFGF 4 ng/ml - - 2/4 wells had colonies growing 2/4 wells mixture of partially
differentiated OCT4
+/OCT4
2
colonies; 2/4 wells fibroblast-like
cells
anti-MUC1* 1 ug/ml - 2/4 wells had colonies fast growing fast growing More undifferentiated cells; 2/4
wells mixture of OCT4
+/OCT4
2
colonies+1 all OCT4
+ colony; 2/4
wells fibroblast-like cells
bFGF 4 ng/ml & anti-MUC1*
1 ug/ml
- - - - 4/4 wells OCT4
2 fibroblast-like
cells
Minimal Stem Cell Growth Media
nothing - - - - 2/4 wells no live cells; 2/4 wells had
OCT4
2 fibroblast-like cells
bFGF 4 ng/ml - - - - 1/4 wells no live cells; 3/4 wells had
OCT4
2 fibroblast-like cells
anti-MUC1* 1 ug/ml - 1/4 wells had colonies fastest growing fastest growing largest colony; 1/4 wells 100%
OCT4
+ undifferentiated colony
covered entire well – 1/4 wells
OCT4
2 fibroblast-like cells; 1/4
wells no live cells
bFGF 4 ng/ml & anti-MUC1*
1 ug/ml
- - - - 2/4 wells no live cells; 2/4 wells
OCT4
2 fibroblast-like cells
doi:10.1371/journal.pone.0003312.t001
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differentiate for 14 days before fixation. Cells were washed with
PBS prior to fixation with 4% paraformaldehyde in 0.1 M
cacodylate buffer for 15 minutes at 4uC. Cells were blocked for
1 hour with 1% BSA and 1% donkey or goat serum in PBS. 0.1%
NP-40 was used with antibodies against intracellular antigens.
Figure 8. Minimal media plus Anti-MUC1* supports the long-term growth of 100% pluripotent hESCs without added bFGF or
conditioned media. H9 hESCs were plated at very low density (4610
4 cells per chamber slide well) over matrigel-coated wells then grown for 5
weeks under a variety of test conditions. The resulted colonies were stained with antibodies against OCT4 and DAPI to assess pluripotency.
Photomicrographs are shown. A,B. The photo shows a single colony that completely filled the well of the chamber slide when hESCs were cultured in
minimal stem cell medium to which Anti-MUC1* was added. OCT4 and DAPI staininig showed that 100% of the cells were pluripotent. The addition of
bFGF or Anti-MUC1* and bFGF cultured under the same conditions produced no pluripotent cell growth (data not shown). C,D. hESCS grown in
media supplemented with Anti-MUC1* and media supplemented with fibroblast (Hs27)-conditioned medium produced partially as well as
completely undifferentiated colonies (pictured). E,F. The addition of bFGF and conditioned medium from fibroblasts, which is standard hESC culture
medium for feeder-free systems, produced only partially undifferentiated colonies; dotted lines indicate edge of pluripotent portion of the colony.
G,H. Cells grown in conditioned media, bFGF and Anti-MUC1* addition resulted only in OCT4-negative, fibroblast-like cells. Scale bars=100 mm.
doi:10.1371/journal.pone.0003312.g008
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for 1 hour at 4uC. The following antibodies were used: OCT4
(Santa Cruz, Clones H-134 and C-10, 1:100 dilution), SSEA4
(Chemicon, Clone MC-813-70, 2.5 mg/ml), Tra 1–60 (Chemicon,
#MAB4360, 2.5 mg/ml), Tra 1–81 (Chemicon, #MAB4381,
5 mg/ml), full-length MUC1 (VU4H5, Santa Cruz Biotechnology,
1:50 dilution; BD Biosciences, Clone HMPV, 1:500 dilution) and
Anti-MUC1* (Minerva, 1:250 dilution), control Fab (Jackson
ImmunoResearch, #315-007-003), MMP14 (Chemicon,
#AB8345, 5 mg/ml), TACE (Chemicon, #AB19027, 5 mg/ml)
and NM23 (Santa Cruz, Clone NM301, 1:100 dilution; BD
Biosciences, Clone 56, 1:100 dilution). Cells were washed 3 times
in PBS for 5 minutes prior to incubation for 30 minutes with
secondary antibodies: AlexaFluor 488 Goat anti-rabbit IgG,
AlexaFluor 555 Goat anti-mouse IgG, AlexaFluor 350 Goat
anti-rabbit IgG (Invitrogen, 1:200); Goat anti-mouse IgM-TR
(Santa Cruz, 1:100). Cells were washed 3 times in PBS for
5 minutes prior to coverslip mounting using an anti-fade mounting
medium (Biomeda). Nuclei were visualized by DAPI staining
(1 mg/ml) for 5 minutes. Immunostained cells were visualized on
an Olympus BX-51 epifluorescent microscope.
ES Cell Short-Term Growth Assay
Quantification of MUC1*-mediated growth. H9 or H14
cells were manually dissected and grown on matrigel-coated wells
of a 96 well plate (BD Falcon). Culture media consisted of hESC
media supplemented with 30% Hs27-conditioned medium and
4 ng/ml bFGF. Medium was changed and antibodies added every
other day at a final concentration of 1 mg/ml for bivalent anti-
MUC1* and 100 mg/ml for monovalent anti-MUC1*.
Experiments were performed in triplicate. 41 hours-post
antibody treatment, live and dead cells were quantified with the
LIVE/DEAD viability/cytotoxicity kit (Molecular Probes),
following manufacturer’s instructions. In other experiments, cells
were quantified using Amido Black (Sigma-Aldrich, #A8181).
Cells were visualized on an Olympus IX70 inverted epifluorescent
microscope and images were captured with a digital camera
(QCapturePro). Fluorescence was measured using a Victor3V
plate reader (Perkin Elmer).
ES Cell Long-Term Growth Assays
OCT4 immunofluorescence of hESC colonies treated with
anti-MUC1*. H9 or H14 cells were trypsin-dissociated and
Figure 9. Anti-MUC1* stimulates the growth of pluripotent stem cells in a dose-dependent manner. H9 hESCs at passage 67 were plated
at very low density (1.9610
4 per well, in triplicate) over matrigel-coated 96-well plates. Cells were cultured in minimal stem cell media, supplemented
with Anti-MUC1* antibody to a final concentration of 0, 80 ng/ml, 0.25 ug/ml, 0.5 ug/ml, 1 ug/ml, or 2 ug/ml and cultured for 10 days. Media plus
antibody was replaced every other day. After 10 days of growth, cells were stained with Amido Black according to manufacturer’s instructions and
absorbance at 570 nm was measured on a microplate reader. Stem cell growth was plotted as a function of Anti-MUC1* concentration. The dashed
line marks the amount of cell growth that was measured for the control, in which cells were grown in 30% conditioned media from Hs27 feeder cells,
supplemented with 4 ng/ml bFGF.
doi:10.1371/journal.pone.0003312.g009
Table 2. H9 hESCs cultured in minimal media for 8 days.
Growth Conditions Confluency Number of colonies Morphology
Minimal Stem Cell Growth Media
NM23 1 nM ,50% 1 colony 1 undifferentiated colonies in 1 of 2 wells
NM23-S120G 1 nM ,50% 3+2 colonies 3 undifferentiated colonies in 1 well; 2
undifferentiated colonies in the other
anti-MUC1* 80 ng/ml ,50% 1 colony 1 undifferentiated colonies in 1 of 2 wells
bFGF 4 ng/ml .25% 0 No colonies; fibroblast-like cells
nothing ,25% 0 No colonies; fibroblast-like cells
Control - 50% Conditioned Media from Hs27 Fibroblast Feeder Cells
bFGF 4 ng/ml ,50% 0 No colonies but single undifferentiated cells
doi:10.1371/journal.pone.0003312.t002
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4610
4 cells/well (H9) or 8.2610
4 cells/well (H14). Media was
changed and antibodies added every other day at a final
concentration of 1 mg/ml for bivalent anti-MUC1* until discrete
colonies were visible.
Culture conditions include ‘minimal stem cell medium’ (hESC
media without feeder-conditioned medium) and Hs27-conditioned
medium, with and without bFGF supplementation. For each
condition, cells were grown in quadruplicate. Cells were washed
with PBS and fixed as described. OCT4 immunostaining was
conducted as described.
Karyotype Analysis of ES Cells
Exponentially growing cultures of cells used in experiments
described were prepared in T-25 flasks pre-seeded with Hs27
feeder cells. Karyotype analysis was performed by Cell Line
Genetics (Madison, WI).
Supporting Information
Figure S1 Stem cells used were of normal karyotype. Karyotype
analysis of H9 cells at A. passage 50 and B. passage 89 show
normal diploid karyotypes.
Found at: doi:10.1371/journal.pone.0003312.s001 (0.79 MB TIF)
Figure S2 Two antibodies that recognize different glycosylation
states of full-length MUC1 detect full-length protein on differen-
tiated H9 stem cells but not on undifferentiated H9s. A. HMPV
antibody that recognizes full-length MUC1 in a glycosylation-
independent manner, does not stain undifferentiated H9 stem cell
colonies. The dashed line indicates the edge of the stem cell
colony. B. Dapi staining verifies that cells are present. C. HMPV
stains the differentiated portion of an H9 colony, to the left of the
solid line, but not the portion to the right that remains
undifferentiated. D. Dapi staining shows that cells are present on
both sides of the solid line demarking the border between
differentiated and undifferentiated. E. VU4H5 antibody that is
able to recognize under-glycosylated full-length MUC1 does not
stain an undifferentiated H9 stem cell colony. F. Dapi staining
verifies that cells are present. G. Control antibody does not stain.
H. Dapi staining. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0003312.s002 (6.76 MB TIF)
Figure S3 Two antibodies that recognize different glycosylation
states of full-length MUC1 detect full-length protein on differen-
tiated H14 stem cells but not on undifferentiated H14s. A. HMPV
antibody that is able to bind to fully glycosylated full-length
MUC1, does not stain undifferentiated H14 stem cell colonies.
The dashed line indicates the edge of the stem cell colony. B. Dapi
staining verifies that cells are present. C. HMPV stains the
differentiated portion of an H14 colony, to the right of the solid
line, but not the portion to the right that remains undifferentiated.
D. Dapi staining shows that cells are present on both sides of the
solid line demarking the border between differentiated and
undifferentiated. E. VU4H5 antibody that is able to recognize
under-glycosylated full-length MUC1 does not stain an undiffer-
entiated H14 stem cell colony. F. Dapi staining verifies that cells
are present. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0003312.s003 (5.27 MB TIF)
Figure S4 H9 hESCs present a 20 kD MUC1 species that is
apparently the cleavage product of MUC1-FL. Lysates were
prepared from a single cell clone of MUC1*-1110 (45 amino acids
of the extracellular domain) transfected HCT-116 cells and H9
hESCs. Equal amounts of the protein were loaded onto a 12%
SDS gel. The gel was run according to standard methods and then
blotted with rabbit polyclonal Anti-MUC1*. Both cells produced
the characteristic 20 kD MUC1* protein band.
Found at: doi:10.1371/journal.pone.0003312.s004 (0.81 MB TIF)
Figure S5 Bivalent Anti-MUC1* stimulates the growth of
pluripotent H9 and H14 hESCs, while the monovalent Fab of
the same antibody killed essentially all of the stem cells.
Undifferentiated H9 and H14 stem cells were cultured in
matrigel-coated plates in media supplemented with 30% condi-
tioned media from Hs27 fibroblast feeder cells and 4 ng/ml bFGF.
Bivalent Anti-MUC1*, the monovalent Fab of Anti-MUC1*, or a
control Fab were added to growing cultures. After twenty-five (25)
hours, the number of live cells was measured using a Calcein AM
assay wherein fluorescence at 535 nm was recorder on a micro
plate reader. A. H9 hESCs. B. H14 hESCS.
Found at: doi:10.1371/journal.pone.0003312.s005 (0.55 MB TIF)
Table 3. H14 hESCs cultured in minimal media for four weeks.
Growth Conditions Week 1
st colony appeared Number of colonies Morphology
Minimal Stem Cell Growth Media
NM23 1 nM Week 2 2 colonies 2 large undifferentiated colonies in 1 of 1 wells;
centers of colonies appear to begin to differentiate
during week 3; by end of week 4, most of each colony
remains undifferentiated
NM23-S120G 1 nM Week 2 7 colonies 7 large undifferentiated colonies in 1 of 1 wells;
centers of colonies appear to begin to differentiate
during week 3; by end of week 4, most of each colony
remains undifferentiated
anti-MUC1* 80 ng/ml Week 2 5 colonies 7 large undifferentiated colonies in 1 of 2 wells;
centers of colonies appear to begin to differentiate
during week 3; by end of week 4, most of each colony
remains undifferentiated
bFGF 4 ng/ml - 0 No colonies
nothing Week 2 2 colonies 2 very small, differentiated colonies
Control - 30% Conditioned Media from Hs27 Fibroblast Feeder Cells
bFGF 4 ng/ml Week 2 5 5 mostly differentiated colonies
doi:10.1371/journal.pone.0003312.t003
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secondary antibody controls that were performed as a part of
the immunocytochemistry experiments as described and pictured
in the figures of the article. Scale bar=100 mm.
Found at: doi:10.1371/journal.pone.0003312.s006 (4.93 MB TIF)
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